Lasa Supergeneri
: LASA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lasa Supergeneri's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lasa Supergenerics Ltd is a specialised manufacturer of veterinary active pharmaceutical ingredients (APIs) and chemicals. The company leverages catalyst chemistry to maintain a significant production footprint in the Indian animal and human healthcare value chain.
Business Model
The company operates through a backward-integrated model, managing the entire process from discovery research to full-scale bulk production. It generates revenue through the manufacturing, processing, and global marketing of veterinary APIs and pharmaceutical chemicals.
Growth Outlook
Growth is driven by the company's focus on its core catalyst chemistry capabilities and its extensive backward integration. The firm aims to expand its reach across the discovery-to-delivery value chain in both animal and human healthcare sectors.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact production and market access.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and raw materials can significantly affect profit margins.
- Sectoral Competition. The veterinary API market is highly competitive, requiring continuous investment in research and development to maintain market share.
- Export Dependency. As a global marketer, the company is exposed to geopolitical risks and currency fluctuations that may impact international trade.
Start your research today
Unlock AI insights, financials, peers and live data on Lasa Supergeneri and 5,000+ companies — free.
Key Metrics
REVENUE
₹25 Cr
TTM · standalone
NET PROFIT
₹-34 Cr
TTM · standalone
EPS
₹-6.30
TTM · standalone
RETURN ON EQUITY
-45.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-45.2%
TTM · standalone
P/E
-1.2x
Q4 FY26 · standalone
EV/EBITDA
-5.7x
Q4 FY26 · standalone
EBITDA MARGIN
-30.3%
TTM · standalone
NET PROFIT MARGIN
3200.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Lasa SupergeneriLASA | ₹35 Cr | -1.11 | -5.84 | -82.4% | -30.3% | -45.3% | -45.2% | -15.0% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Lasa Supergeneri
: LASA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lasa Supergeneri's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lasa Supergenerics Ltd is a specialised manufacturer of veterinary active pharmaceutical ingredients (APIs) and chemicals. The company leverages catalyst chemistry to maintain a significant production footprint in the Indian animal and human healthcare value chain.
Business Model
The company operates through a backward-integrated model, managing the entire process from discovery research to full-scale bulk production. It generates revenue through the manufacturing, processing, and global marketing of veterinary APIs and pharmaceutical chemicals.
Growth Outlook
Growth is driven by the company's focus on its core catalyst chemistry capabilities and its extensive backward integration. The firm aims to expand its reach across the discovery-to-delivery value chain in both animal and human healthcare sectors.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact production and market access.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and raw materials can significantly affect profit margins.
- Sectoral Competition. The veterinary API market is highly competitive, requiring continuous investment in research and development to maintain market share.
- Export Dependency. As a global marketer, the company is exposed to geopolitical risks and currency fluctuations that may impact international trade.
Start your research today
Unlock AI insights, financials, peers and live data on Lasa Supergeneri and 5,000+ companies — free.
Key Metrics
REVENUE
₹25 Cr
TTM · standalone
NET PROFIT
₹-34 Cr
TTM · standalone
EPS
₹-6.30
TTM · standalone
RETURN ON EQUITY
-45.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-45.2%
TTM · standalone
P/E
-1.2x
Q4 FY26 · standalone
EV/EBITDA
-5.7x
Q4 FY26 · standalone
EBITDA MARGIN
-30.3%
TTM · standalone
NET PROFIT MARGIN
3200.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26